Flamogrel (clopidogrel) coated tablets 75 mg. №30

$8.00

Manufacturer: India

Prevention of atherothrombosis in adults in patients who have suffered a myocardial infarction (treatment begins a few days later, but not later than 35 days after its occurrence), ischemic stroke (treatment begins 7 days later, but not later than 6 months after its occurrence) , or who have been diagnosed with peripheral artery disease (arterial damage and atherothrombosis of the lower extremities); in patients with acute coronary syndrome: with acute coronary syndrome without St segment elevation (unstable angina or myocardial infarction without q wave), including in patients who had a stent installed during percutaneous coronary angioplasty, in combination with acetylsalicylic acid with acute myocardial infarction with St segment elevation in combination with acetylsalicylic acid (in patients receiving standard medical treatment and who are indicated for thrombolytic therapy).

Category:

Description

FLAMOGREL COMPOSITION
active substance: clopidogrel

1 coated tablet contains clopidogrel bisulfate in terms of clopidogrel 75 mg

excipients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, low-substituted hydroxypropyl cellulose, magnesium stearate, talc, silicon dioxide, hydrogenated castor oil, film coating SOL Code IC-S-279 (Brown) (contains titanium dioxide (E 171) and iron oxide red (E172)), isopropyl alcohol, dichloromethane.

FLAMOGREL DOSAGE FORM
Film-coated tablets.

FLAMOGREL PHARMACOLOGICAL GROUP
Antithrombotic agents. ATC code B01A C04.

INDICATIONS
Prevention of manifestations of atherothrombosis in adults

in patients who have had myocardial infarction (start of treatment – a few days, but no later than 35 days after onset), ischemic stroke (start of treatment – 7 days, but no later than 6 months after onset), or who are diagnosed peripheral arterial disease (damage to the arteries and atherothrombosis of the vessels of the lower extremities)
in patients with acute coronary syndrome:
with acute coronary syndrome without ST-segment elevation (unstable angina pectoris or myocardial infarction without Q wave), including in patients who received a stent during percutaneous coronary angioplasty in combination with acetylsalicylic acid (ASA)
with acute myocardial infarction with ST segment elevation in combination with ASA (in patients receiving standard medical treatment and for whom thrombolytic therapy is indicated).
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

Clopidogrel in combination with ASA is indicated for adult patients with atrial fibrillation who have at least one risk factor for vascular events, in which there are contraindications to treatment with vitamin K antagonists (VKA) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events , including stroke.

CONTRAINDICATIONS
Hypersensitivity to the active substance or to any component of the drug. Severe liver failure. Acute bleeding (such as an ulcer or intracranial hemorrhage).

DOSAGE AND APPLICATION
Adults and elderly patients. Flamogrel 75 is prescribed 75 mg once a day, regardless of food intake.

In patients with acute coronary syndrome without ST-segment elevation (unstable angina pectoris or myocardial infarction without a Q wave on the ECG), clopidogrel treatment begins with a single loading dose of 300 mg, and then continues at a dose of 75 mg once a day (with ASA at a dose of 75- 325 mg per day). Since the use of higher doses of ASA increases the risk of bleeding, it is recommended not to exceed the dose of ASA 100 mg. The optimal duration of treatment has not been formally established. The results of clinical studies support the use of the drug for up to 12 months, and the maximum effect was observed after 3 months of treatment.

75 mg once a day, starting with a single loading dose of 300 mg in combination with ASA, with or without thrombolytic drugs. Treatment of patients over 75 years of age begins without a loading dose of clopidogrel. Combination therapy should be started as early as possible after symptom onset and continued for at least four weeks. The benefit of combining clopidogrel with ASA for more than four weeks in this disease has not been studied.

In patients with atrial fibrillation, clopidogrel is used in a single dose

If a dose is missed:

if less than 12:00 has passed since the moment when it was necessary to take the next dose: the patient should immediately take the missed dose, and take the next dose at the usual time.
if more than 12:00 has passed, the patient should take the next regular dose at the usual time but not double the dose in order to compensate for the missed dose.